Literature DB >> 16194540

One-compound-multiple-targets strategy to combat Alzheimer's disease.

Hong-Yu Zhang1.   

Abstract

The present one-drug-one-target paradigm in drug discovery has been considered partially responsible for the more-funding-less-drug predicament in modern pharmaceutical industry. To hit the multiple targets implicated in complex diseases, two strategies, based on multicomponent or single-ingredient, are conceivable. Although the latter is more difficult to be fulfilled than the former, the recent progress made in the fight against Alzheimer's disease (AD) has brought us the first light of success of the latter strategy. In this review, both synthetic and natural multipotent agents are described, which hit two or more targets implicated in AD, e.g., acetylcholinesterase, monoamine oxidase, amyloid-beta, tau protein, metal ions and reactive oxygen species. Nevertheless, due to the potential risks in safety, absorbability and pharmacokinetics of synthetic multipotent agents, natural counterparts seem more promising in the future development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16194540     DOI: 10.1016/j.febslet.2005.09.006

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  22 in total

1.  How many drugs are catecholics.

Authors:  Da-Peng Yang; Hong-Fang Ji; Guang-Yan Tang; Wei Ren; Hong-Yu Zhang
Journal:  Molecules       Date:  2007-04-30       Impact factor: 4.411

Review 2.  Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim.

Authors:  Orly Weinreb; Silvia Mandel; Orit Bar-Am; Tamar Amit
Journal:  J Neural Transm (Vienna)       Date:  2011-03-01       Impact factor: 3.575

3.  Design, synthesis and evaluation of indole derivatives as multifunctional agents against Alzheimer's disease.

Authors:  Ireen Denya; Sarel F Malan; Adaze B Enogieru; Sylvester I Omoruyi; Okobi E Ekpo; Erika Kapp; Frank T Zindo; Jacques Joubert
Journal:  Medchemcomm       Date:  2018-01-16       Impact factor: 3.597

4.  Synthesis of novel perillyl-dihydropyrimidinone hybrids designed for antiproliferative activity.

Authors:  Vinicius Vendrusculo; Vanessa P de Souza; Luiz Antônio M Fontoura; Marcelo G M D'Oca; Thais P Banzato; Paula A Monteiro; Ronaldo A Pilli; João Ernesto de Carvalho; Dennis Russowsky
Journal:  Medchemcomm       Date:  2018-07-31       Impact factor: 3.597

Review 5.  Hybrids: a new paradigm to treat Alzheimer's disease.

Authors:  Manjinder Singh; Maninder Kaur; Navriti Chadha; Om Silakari
Journal:  Mol Divers       Date:  2015-09-02       Impact factor: 2.943

Review 6.  Novel anti-Alzheimer's dimer Bis(7)-cognitin: cellular and molecular mechanisms of neuroprotection through multiple targets.

Authors:  Wenming Li; Marvin Mak; Hualiang Jiang; Qinwen Wang; Yuanping Pang; Kaixian Chen; Yifan Han
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

7.  Glucosamine and Its Analogues as Modulators of Amyloid-β Toxicity.

Authors:  Ana R Araújo; Vânia I B Castro; Rui L Reis; Ricardo A Pires
Journal:  ACS Med Chem Lett       Date:  2021-03-24       Impact factor: 4.345

8.  Stabilization of curcumin by complexation with divalent cations in glycerol/water system.

Authors:  Bachar Zebib; Zéphirin Mouloungui; Virginie Noirot
Journal:  Bioinorg Chem Appl       Date:  2010-06-16       Impact factor: 7.778

9.  Theoretical study of the impact of metal complexation on the reactivity properties of Curcumin and its diacetylated derivative as antioxidant agents.

Authors:  Nor El Houda Medigue; Zohra Bouakouk-Chitti; Lina Linda Bechohra; Safia Kellou-Taïri
Journal:  J Mol Model       Date:  2021-05-31       Impact factor: 1.810

10.  Pharmacological characterization of memoquin, a multi-target compound for the treatment of Alzheimer's disease.

Authors:  Valeria Capurro; Perrine Busquet; Joao Pedro Lopes; Rosalia Bertorelli; Glauco Tarozzo; Maria Laura Bolognesi; Daniele Piomelli; Angelo Reggiani; Andrea Cavalli
Journal:  PLoS One       Date:  2013-02-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.